Medicine:Azficel-T
From HandWiki
Short description: Medication for nasolabial fold wrinkles
 | This article provides insufficient context for those unfamiliar with the subject. (March 2021) (Learn how and when to remove this template message) |
| Clinical data | |
|---|---|
| Trade names | Laviv |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intradermal |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
Azficel-T, sold under the brand name Laviv, is a cell therapy product for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.[1][2][3] It consists of fibroblasts harvested from the patient's own skin.[2]
It was approved for medical use in the United States in June 2011.[2]
References
- ↑ 1.0 1.1 "Laviv (Azficel-T)". 22 July 2017. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/laviv-azficel-t.
- ↑ 2.0 2.1 2.2 2.3 "Autologous Fibroblasts". 29 June 2017. https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm260485.htm.
- ↑ "Laviv (azficel-T) Suspension for Intradermal Injection" (PDF). https://www.fda.gov/media/80838/download.
Further reading
- "A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles". Dermatol Surg 38 (7 Pt 2): 1234–43. July 2012. doi:10.1111/j.1524-4725.2012.02349.x. PMID 22409385.
External links
- "Azficel-T". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/azficel-t.
- "Laviv (azficel-T)". 28 September 2019. https://reference.medscape.com/drug/laViv-azficel-t-999666.
- Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at ClinicalTrials.gov
 |  |
